Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card 2 Control Swab Kit

K173502 · Alere Scarborough, Inc. · PSZ · Dec 13, 2017 · Microbiology

Device Facts

• Record ID: K173502
• Device Name: Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card 2 Control Swab Kit
• Applicant: Alere Scarborough, Inc.
• Product Code: PSZ · Microbiology
• Decision Date: Dec 13, 2017
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 866.3328
• Device Class: Class 2

Intended Use

The Alere BinaxNOW Influenza A & B Card 2 is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results are presumptive and should be confirmed by cell culture or an FDA-cleared influenza A and B molecular assay. Negative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions. Alere BinaxNOW Influenza A & B Card 2 must be read by the Alere Reader. Performance characteristics for influenza A were established during the 2015-2016 influenza season when influenza A/H3N2 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

Device Story

Device consists of Alere BinaxNOW Influenza A & B Card 2 (immunochromatographic assay) and Alere Reader (benchtop instrument). Input: nasopharyngeal or nasal swab specimens eluted in solution, applied to test card. Reader uses camera to capture image of test strip; analyzes intensity of test and control lines; displays qualitative results (positive/negative/invalid). Used in professional medical laboratory or point-of-care settings. Software modification enables 'Walk Away' mode (Reader times test after insertion) alongside existing 'Read Now' mode. Operator enters Subject/Operator ID via barcode scanner or manual entry. Output displayed on screen; can be printed or uploaded to LIS/LIM. Facilitates rapid diagnosis; aids clinical decision-making regarding patient management.

Clinical Evidence

No clinical data provided. Substantial equivalence is supported by bench testing of the software modification to ensure the new 'Walk Away' mode functions correctly and maintains the performance characteristics of the previously cleared device.

Technological Characteristics

Immunochromatographic membrane assay; cardboard hinged test card. Alere Reader is a camera-based benchtop instrument. Connectivity via USB for printer and LIS/LIM integration. Software-controlled timing and image analysis. Qualitative result output.

Indications for Use

Indicated for qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal and nasal swab specimens to aid in rapid differential diagnosis of influenza A and B viral infections.

Regulatory Classification

Identification

An influenza virus antigen detection test system is a device intended for the qualitative detection of influenza viral antigens directly from clinical specimens in patients with signs and symptoms of respiratory infection. The test aids in the diagnosis of influenza infection and provides epidemiological information on influenza. Due to the propensity of the virus to mutate, new strains emerge over time which may potentially affect the performance of these devices. Because influenza is highly contagious and may lead to an acute respiratory tract infection causing severe illness and even death, the accuracy of these devices has serious public health implications.

Special Controls

*Classification.* Class II (special controls). The special controls for this device are:(1) The device's sensitivity and specificity performance characteristics or positive percent agreement and negative percent agreement, for each specimen type claimed in the intended use of the device, must meet one of the following two minimum clinical performance criteria: (i) For devices evaluated as compared to an FDA-cleared nucleic acid based-test or other currently appropriate and FDA accepted comparator method other than correctly performed viral culture method: (A) The positive percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent. (B) The negative percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent. (ii) For devices evaluated as compared to correctly performed viral culture method as the comparator method: (A) The sensitivity estimate for the device when testing for influenza A must be at the point estimate of at least 90 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 80 percent. The sensitivity estimate for the device when testing for influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent. (B) The specificity estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent. (2) When performing testing to demonstrate the device meets the requirements in paragraph (b)(1) of this section, a currently appropriate and FDA accepted comparator method must be used to establish assay performance in clinical studies. (3) Annual analytical reactivity testing of the device must be performed with contemporary influenza strains. This annual analytical reactivity testing must meet the following criteria: (i) The appropriate strains to be tested will be identified by FDA in consultation with the Centers for Disease Control and Prevention (CDC) and sourced from CDC or an FDA-designated source. If the annual strains are not available from CDC, FDA will identify an alternative source for obtaining the requisite strains. (ii) The testing must be conducted according to a standardized protocol considered and determined by FDA to be acceptable and appropriate. (iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling. If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included. The results must be presented as part of the device's labeling in a tabular format, which includes the detailed information for each virus tested as described in the certificate of authentication, either by: (A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where the analytical reactivity testing data can be found; or (B) In the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access. (4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain: (i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate. The procedure and location of testing may depend on the nature of the emerging virus. (ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by: (A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or (B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.

Predicate Devices

• Alere BinaxNOW Influenza A & B Card 2 and Alere Reader (k162642)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.

December 13, 2017

Alere Scarborough, Inc. Benjamin Crystal Manager, Regulatory Affairs - Infectious Disease 10 Southgate Road Scarborough, Maine 04074

Re: K173502

Trade/Device Name: Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card 2 Control Swab Kit Regulation Number: 21 CFR 866.3328 Regulation Name: Influenza virus antigen detection test systems Regulatory Class: Class II Product Code: PSZ Dated: November 10, 2017 Received: November 13, 2017

Dear Benjamin Crystal:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR

{1}------------------------------------------------

803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

## Steven R. Gitterman -S for

Uwe Scherf, Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K173502

#### Device Name

Alere BinaxNOW Influenza A & B Card 2 and Alere Reader

#### Indications for Use (Describe)

The Alere BinaxNOW Influenza A & B Card 2 is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results are presumptive and should be confirmed by cell culture or an FDA-cleared influenza A and B molecular assay. Negative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions. Alere BinaxNOW Influenza A & B Card 2 must be read by the Alere Reader.

Performance characteristics for influenza A were established during the 2015-2016 influenza A/H3N2 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

| Type of Use (Select one or both, as applicable) |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <div> <span> <span style="font-size:16px">❌</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> <span> <span style="font-size:16px">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> |

CONTINUE ON A SEPARATE PAGE IF NEEDEDThis section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k173502

#### SUBMITTER

Alere Scarborough, Inc. 10 Southgate Road Scarborough, ME 04074 Establishment Registration Number: 1221359

#### PRIMARY CONTACT PERSON

Benjamin Crystal [phone] (Office) [phone] (FAX) [e-mail] (email)

#### SECONDARY CONTACT PERSON

Angela Drysdale (207) 415 - 1393 (Mobile) (207) 730 – 5737 (Office) [e-mail] (email)

#### DATE PREPARED

11/7/2017

### TRADE NAME

Alere BinaxNOW® Influenza A & B Card 2 Alere ™ Reader

### COMMON NAME

BinaxNOW® Influenza A & B Card 2, BinaxNOW® Card 2, Alere Influenza A & B 2, BinaxNOW® Flu Card 2/Reader, Lateral Flow Reader, Card Test Analyzer

### CLASSIFICATION NAME

Influenza virus antigen detection test system 21 CFR 866.3328

### CLASSIFICATION

Class II

### PRODUCT CODE

PSZ, Devices detecting influenza A, B and C virus antigens

{4}------------------------------------------------

# PANEL

Microbiology (83)

## PREDICATE DEVICE

Alere BinaxNOW® Influenza A & B Card 2 and Alere™ Reader, k162642

## DEVICE DESCRIPTION

The Alere BinaxNOW® Influenza A & B Card 2 is an immunochromatographic membrane assay that detects influenza type A and B nucleoprotein antigens in respiratory specific antibodies and a control antibody are immobilized onto a membrane support as three distinct lines and combined with other reagents/pads to construct a test strip is mounted inside a cardboard, book-shaped hinged test card.

Swab specimens require a sample preparation step, in which the sample is eluted off the swab into Elution Solution. Sample is added to the test strip and the test card is closed. Test results are interpreted at 15 minutes based on the presence or absence of Sample Lines. Alere BinaxNOW® Influenza A & B Card 2 test results must be read by the Alere™ Reader.

The Alere™ Reader is an easy to use bench top instrument that can be used near patient and in laboratory settings which will interpret, capture and transmit test results. The Alere™ Reader is a camera based instrument that detects the presence and identity of the Alere BinaxNOW® Influenza A& B Card 2 assay, analyzes the intensity of the test and control lines and displays the results (positive or invalid) on a display screen. The screen is intended as a means of user interface informing the user how to operate the Reader and to display test results, including any errors. Data can be retrieved and downloaded by the operator at any time after testing and uploaded to the hospital LIS/LIM system, if desired. Operator ID and Subject ID can be entered manually or via the provided barcode scanner. An external printer can be attached via USB to the Alere™ Reader to print test results.

### INTENDED USE

The Alere BinaxNOW® Influenza A & B Card 2 is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results are presumptive and should be confirmed by cell culture or an FDA-cleared influenza A and B molecular assay. Neqative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions. Alere BinaxNOW® Influenza A & B Card 2 must be read by the Alere™ Reader.

Performance characteristics for influenza A were established during the 2015-2016 influenza season when influenza A/H3N2 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing.

{5}------------------------------------------------

Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

### COMPARISON TO THE PREDICATE

The purpose of this Special 510k submission is to bring to market a modification of the software contained on the Alere™ Reader. There have been no changes to the Alere BinaxNOW® Influenza A & B Card 2 test. To facilitate flexibility in the testing workflow of the software has been modified to allow the user to use the Alere™ Reader according to the current procedure, utilizing "Read Now" mode, where the Alere BinaxNOW® Influenza A & B Card 2 assay is performed and timed on the bench and inserted in the Alere™ Reader at the read time, as well as, "Walk Away" mode, where the Alere BinaxNOW® Influenza A & B Card 2 assay is performed and inserted in the Alere™ Reader upon closing. The Alere™ Reader will time the test for the user, read the test and report the read time. In addition to the new "Walk Away" mode, the modified software incorporates additional updates and enhancements to the Alere™ Reader.

In the table below, the Alere BinaxNOW® Influenza A & B Card 2 with the modified Alere™ Reader is compared to the legally marketed predicate device, the 510(k) cleared Alere BinaxNOW® Influenza A & B Card 2 and Alere™ Reader.

| Parameter | Alere BinaxNOW® Influenza A & B Card 2<br>and Alere™ Reader<br>(with software modification) | Alere BinaxNOW® Influenza A & B<br>Card 2 and Alere™ Reader<br>(k162642) |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| FDA Product Code | PSZ | Same |
| Assay Target | Influenza A, Influenza B | Same |
| Intended Use | The Alere BinaxNOW® Influenza A & B Card 2 is<br>an in vitro immunochromatographic assay for the<br>qualitative detection of influenza A and B<br>nucleoprotein antigens in nasopharyngeal (NP)<br>swab and nasal swab specimens. It is intended to<br>aid in the rapid differential diagnosis of influenza<br>A and B viral infections. Negative test results are<br>presumptive and should be confirmed by cell<br>culture or an FDA-cleared influenza A and B<br>molecular assay. Negative test results do not<br>preclude influenza viral infection and should not<br>be used as the sole basis for treatment or other<br>patient management decisions. Alere<br>BinaxNOW® Influenza A & B Card 2 must be read<br>by the Alere™ Reader.<br><br>Performance characteristics for influenza A were<br>established during the 2015-2016 influenza<br>season when influenza A/H3N2 and A/H1N1<br>pandemic were the predominant influenza A<br>viruses in circulation. When other influenza A<br>viruses are emerging, performance characteristics | Same |

{6}------------------------------------------------

| Parameter | Alere BinaxNOW® Influenza A & B Card 2<br>and Alere™ Reader<br>(with software modification) | Alere BinaxNOW® Influenza A & B<br>Card 2 and Alere™ Reader<br>(k162642) |
|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| | may vary.<br><br>If infection with a novel influenza A virus is<br>suspected based on current clinical and<br>epidemiological screening criteria recommended<br>by public health authorities, specimens should be<br>collected with appropriate infection control<br>precautions for novel virulent influenza viruses<br>and sent to state or local health department for<br>testing. Viral culture should not be attempted in<br>these cases unless a BSL 3+ facility is available to<br>receive and culture specimens. | |
| Intended<br>Environment for<br>Use | Professional use, in a medical laboratory or point<br>of care (CW170003) | Same |
| Instrumentation | Alere™ Reader | Same |
| <b>Assay Information</b> | | |
| Sample Type | Nasal and Nasopharyngeal Swab | Same |
| Detection Format | The camera-based Alere™ Reader detects the<br>presence and identity of the Alere BinaxNOW®<br>Influenza A & B Card 2 assay, analyzes the<br>intensity of the sample and control line and<br>reports the results (positive, negative, or invalid)<br>on a display screen. | Same |
| Internal Control | Yes | Same |
| Assay Result | Qualitative | Same |
| Time to Result | 15 minutes | Same |